
Search Clinical Trials
Sponsor Condition of Interest |
---|
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Tra1
Arkansas Children's Hospital Research Institute
Hematopoietic Cell Transplant
Solid Organ Transplant
Respiratory Viral Infection
The participants are being asked to take part in this clinical trial, a type of research
study, because the participants are scheduled to receive or have recently received a
hematopoietic cell transplant (HCT) or a solid organ transplant (SOT).
Primary Objective
To determine if pre-transplant scr1 expand
The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT). Primary Objective To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors. Secondary Objectives: - To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors. - To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors . Type: Observational Start Date: Dec 2022 |
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
Temple University
COPD
Parallel-group, prospective, randomized, controlled phase III trial of home High flow
Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical
care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients
with moderate to very severe COPD at1 expand
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks. Type: Interventional Start Date: Feb 2022 |
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
Darcy Krueger
Tuberous Sclerosis Complex
Epilepsy
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to
evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in
TSC infants.
This study is supported by research funding from the Office of Orphan Products Division
(OOPD) of the US F1 expand
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA). Type: Interventional Start Date: Oct 2021 |
Study of Pembrolizumab and M032 (NSC 733972)
University of Alabama at Birmingham
Glioblastoma Multiforme
Anaplastic Astrocytoma
Gliosarcoma
This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the
safety and tolerability of Pembrolizumab when given in conjunction with M032, an
Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and perform the Phase II
portion using a Recommended Phase 2 Dose (RP2D) of1 expand
This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and perform the Phase II portion using a Recommended Phase 2 Dose (RP2D) of M032 (provided by the Phase I) when given in conjunction with Pembrolizumab for recurrent malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, or glio-sarcoma). Type: Interventional Start Date: Feb 2022 |
Ridge Augmentation Using Allograft Particles Hydrated with or Without Recombinant Human Platelet-De1
University of Alabama at Birmingham
Dental Implant
Bone Loss
This study will compare two techniques to achieve increase in ridge dimensions as a
preparation for dental implants using a resorbable barrier membrane and bone particulate
allogenic graft hydrated with saline or a growth factor called Recombinant Human
Platelet-Derived Growth Factor (rhPDGF). expand
This study will compare two techniques to achieve increase in ridge dimensions as a preparation for dental implants using a resorbable barrier membrane and bone particulate allogenic graft hydrated with saline or a growth factor called Recombinant Human Platelet-Derived Growth Factor (rhPDGF). Type: Interventional Start Date: Aug 2021 |
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon1
University of Alabama at Birmingham
Juxtarenal Aortic Aneurysm
Suprarenal Aortic Aneurysm
Thoracoabdominal Aortic Aneurysm
Penetrating Aortic Ulcer
This is a single-center study to evaluate the safety and effectiveness of three
investigational devices, the Cook Custom Aortic Endograft, the Zenith t-Branch
Endovascular Graft, and the Surgeon-Modified Endografts in the treatment of aortic
pathologies involving the visceral vessels.
The three in1 expand
This is a single-center study to evaluate the safety and effectiveness of three investigational devices, the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and the Surgeon-Modified Endografts in the treatment of aortic pathologies involving the visceral vessels. The three investigational devices offer an endovascular approach to treat complex aortic pathologies that cannot be treated with commercially available devices. This customized, endovascular approach has the potential to decrease hospital length of stay, pulmonary complications, and in-hospital mortality. Type: Interventional Start Date: Jun 2014 |
Nasal Potential Difference (NPD) Protocol in Chronic Rhinosinusitis
University of Alabama at Birmingham
Rhinosinusitis
The purpose of this study is to determine if acquired (partial) Cystic Fibrosis
Transmembrane Conductance Regulator (CFTR) deficiency contributes substantially to the
pathogenic mechanisms underlying Chronic Rhinosinusitis (CRS), creating a localized
environment that impairs mucociliary clearance (1 expand
The purpose of this study is to determine if acquired (partial) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) deficiency contributes substantially to the pathogenic mechanisms underlying Chronic Rhinosinusitis (CRS), creating a localized environment that impairs mucociliary clearance (MCC). Type: Observational Start Date: Jan 2015 |
Infant-Maternal Partnership and Cognitive Training Study for Preterm Infants
University of Alabama at Birmingham
Child Development
Infant Development
Infant, Premature, Diseases
This study will test the hypothesis that in preterm infants a caregiver-implemented early
developmental intervention (EDI) using finger puppets to develop joint attention and
encourage interactive communication with routine EDI care including Bookworm training
compared with routine EDI care includi1 expand
This study will test the hypothesis that in preterm infants a caregiver-implemented early developmental intervention (EDI) using finger puppets to develop joint attention and encourage interactive communication with routine EDI care including Bookworm training compared with routine EDI care including Bookworm training alone will increase the Ages and Stages Questionnaire® score at 12 months corrected age. Type: Interventional Start Date: Nov 2024 |
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
Noha Mohamed Sharafeldin
Multiple Myeloma
This is a pilot feasibility trial among older adults (≥60y) scheduled to undergo
Autologous Stem Cell transplantation at UAB. Participants will be randomized into either
a prehabilitation program or an attention control group before their transplant. The
primary outcomes will be feasibility and sec1 expand
This is a pilot feasibility trial among older adults (≥60y) scheduled to undergo Autologous Stem Cell transplantation at UAB. Participants will be randomized into either a prehabilitation program or an attention control group before their transplant. The primary outcomes will be feasibility and secondary outcomes include changes in physical function at the time of transplant and at 12 weeks follow up. Type: Interventional Start Date: Jul 2023 |
Cancer and Aging Resilience Evaluation in Older Adults with Hematologic Malignancies: the CARE-Heme1
University of Alabama at Birmingham
Multiple Myeloma
Amyloidosis
Plasma Cell Leukemia
The primary purpose of this protocol is to create a registry of older (≥50 years old)
patients with Hematologic Malignancies. Our main objectives include: To understand the
prevalence of frailty and geriatric impairments among patients aged ≥50y and above
diagnosed with a hematologic malignancy at1 expand
The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population. Type: Observational [Patient Registry] Start Date: Jul 2020 |
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell1
University of Alabama at Birmingham
Head and Neck Squamous Cell Carcinoma
This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron
Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately
determine size and location of primary tumors compared to standard of care
Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagno1 expand
This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standard of care Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagnosed patients with head and neck squamous cell carcinoma (HNSCC) who are undergoing surgical resection. This study is for imaging purposes only and is not a treatment study. The results of this study will not change the clinical treatment plan. Type: Interventional Start Date: Dec 2025 |
Effect of Reparel Knee Sleeve with Knee Injection
University of Alabama at Birmingham
Osteoarthritis, Knee
The goals of treating knee osteoarthritis (OA) is to improve or maintain quality of life,
mobility and function, pain relief, and improve inflammation. The different treatment
options for knee OA have been extensively studied and implemented, but the optimum
treatment is still undecided. There is a1 expand
The goals of treating knee osteoarthritis (OA) is to improve or maintain quality of life, mobility and function, pain relief, and improve inflammation. The different treatment options for knee OA have been extensively studied and implemented, but the optimum treatment is still undecided. There is a belief that anti-inflammatory sleeve technology may be beneficial in treating knee OA. The purpose of this study is to determine if the Reparel™ knee sleeve results in superior mobility, functionality, and pain outcomes as compared to a placebo knee sleeve in managing knee OA. Type: Interventional Start Date: Jun 2022 |
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
Multiple Myeloma
This is a phase II interventional study evaluating the use of minimal residual disease by
next generation sequencing to defer autologous hematopoietic stem cell transplantation
(AHCT) in patients with newly diagnosed multiple myeloma. expand
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma. Type: Interventional Start Date: Sep 2021 |
Investigating Inhibitory Control Networks in Parkinson's Disease
University of Alabama at Birmingham
Parkinson Disease
The purpose of this study is to investigate the brain activity associated with non-motor
symptoms of movement disorders, including Parkinson's disease and essential tremor. These
movement disorders commonly have significant non-motor features also, including
depression, cognitive impairment, decrea1 expand
The purpose of this study is to investigate the brain activity associated with non-motor symptoms of movement disorders, including Parkinson's disease and essential tremor. These movement disorders commonly have significant non-motor features also, including depression, cognitive impairment, decreased attention, and slower processing speeds. The investigators are interested in the brain activity associated with these symptoms, and perform recordings of the surface of the brain, in addition to the typical recordings the investigators perform, during routine deep brain stimulation (DBS) surgery. Type: Interventional Start Date: Apr 2021 |
The Fit with Us Study
University of Alabama at Birmingham
Mobility Limitations
Disability Physical
Telehealth
Health Coaching
Physical Activity
The purpose of this 32 week study is to use an innovative experimental design known as
SMART (Sequential Multiple Assignment Randomized Trial), which will allow us to determine
the best way to sequence the delivery of teleexercise (referred to as an adaptive
intervention), combined with predictive1 expand
The purpose of this 32 week study is to use an innovative experimental design known as SMART (Sequential Multiple Assignment Randomized Trial), which will allow us to determine the best way to sequence the delivery of teleexercise (referred to as an adaptive intervention), combined with predictive analytics on participant adherence in a stepped program of physical activity interventions. All 257 participants will have access to a library of recorded video exercise content, and a weekly wellness article. Some participants will receive health coaching calls (1st randomization). Analytic data will be used to determine which participants are responding or not responding to the intervention. Participants not responding after 4 weeks will receive either live one on one or group exercise training (2nd randomization). After 8 weeks, the participant will receive only pre recorded exercise content and articles for another 8 weeks. After final surveys, participants will have open access to the website for another 16 weeks where we will passively observe their fitbit and website data. The study outcomes are: The effectiveness of the adaptive interventions Exploring mediating and moderating variables Sensitivity analysis of the predictive analytics Type: Interventional Start Date: Sep 2024 |
Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord In1
University of Alabama at Birmingham
Spinal Cord Injuries
Gut Microbiome
The Investigators will recruit 35 participants with acute SCI (within 6 weeks of injury)
Fasting blood collection and bowel function survey will be conducted 3 times: at baseline
[within 6 weeks of injury], 6, and 12 months after SCI. Stool will be collected for gut
microbiome analysis 3 times. expand
The Investigators will recruit 35 participants with acute SCI (within 6 weeks of injury) Fasting blood collection and bowel function survey will be conducted 3 times: at baseline [within 6 weeks of injury], 6, and 12 months after SCI. Stool will be collected for gut microbiome analysis 3 times. Type: Observational Start Date: Oct 2023 |
An Accessible and Inclusive Artificial Intelligence Assisted Chronic Disease Self-Management Telehe1
University of Alabama at Birmingham
Disability Physical
Chronic Condition
Chronic Conditions, Multiple
The purpose of this study to pilot test an accessible and inclusive artificial
intelligence (AI)-assisted, individualized, family-focused lifestyle modification
intervention (AI4CHRON) for health-related quality of life for adults with impaired
mobility and chronic medical conditions. expand
The purpose of this study to pilot test an accessible and inclusive artificial intelligence (AI)-assisted, individualized, family-focused lifestyle modification intervention (AI4CHRON) for health-related quality of life for adults with impaired mobility and chronic medical conditions. Type: Interventional Start Date: Feb 2024 |
A Motion Exergaming Approach for Symptom Management: HNC
University of Alabama at Birmingham
Head and Neck Cancer
This overall objective of the RCT is to test an intervention to overcome the PA barriers
for head and neck cancer (HNC) patients during the first 6 months after their treatment.
PAfitME stands for a personalized Physical Activity intervention with fitness graded
Motion Exergames. PAfitME is deliver1 expand
This overall objective of the RCT is to test an intervention to overcome the PA barriers for head and neck cancer (HNC) patients during the first 6 months after their treatment. PAfitME stands for a personalized Physical Activity intervention with fitness graded Motion Exergames. PAfitME is delivered via a tested mix of FaceTime calls and home visits, uses commercially available exergaming platforms (Nintendo Switch). We propose the following specific aims: (1) When compared to an attention control group, determine the effect of PAfitME on fatigue and musculoskeletal pain at week 6, when controlling for age and sex; (2) when compared to an attention control group, determine the effect of PAfitME on functional status and QOL at week 6, when controlling for age and sex; and (3) explore if PA self-efficacy, PA enjoyment, and exergame minutes mediate the effect of PAfitME on fatigue and musculoskeletal pain. This study will evaluate 150 post-treatment (radiation, chemotherapy, or chemoradiation) HNC patients in an RCT with an attention control. For 6 weeks, the experimental (PAfitME) group will receive the PAfitME intervention, and the attention control group will receive NCI-based survivorship education and exergame equipment. For Aims 1 and 2, using an intention-to-treat framework, we will fit a series of linear mixed effects models with each of the outcome variables. For Aim 3, we will conduct our exploratory analyses in ml_mediation (STATA 15), which will compute direct and indirect effects for multi-level data. Type: Interventional Start Date: Aug 2020 |
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
University of Alabama at Birmingham
Alzheimer Disease
The primary objective of this study is to measure the concentration and the regional
brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in
participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions
between race and vascular risk factors, br1 expand
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the primary outcome of this imaging study. Type: Interventional Start Date: Apr 2018 |
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Duke University
Rheumatic Joint Disease
Continuation of the CARRA Registry as described in the protocol will support data
collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will
form the basis for future CARRA studies. In particular, this observational registry will
be used to answer pressing questions abo1 expand
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions. Type: Observational [Patient Registry] Start Date: Jul 2015 |
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease1
University of Alabama at Birmingham
Decision Making, Shared
Family Caregiving
Chronic Kidney Disease
Using a highly innovative methodology, the Multiphase Optimization Strategy (MOST), the
purpose of this study is to pilot test, an optimization trial approach to develop and
refine the decision partnering skills of persons with stage 4 chronic kidney disease and
their caregivers. Using a 2x2x2 full1 expand
Using a highly innovative methodology, the Multiphase Optimization Strategy (MOST), the purpose of this study is to pilot test, an optimization trial approach to develop and refine the decision partnering skills of persons with stage 4 chronic kidney disease and their caregivers. Using a 2x2x2 full factorial design, 64 dyads (patients and one identified caregiver) will be randomized to receive one or more lay coach-delivered decision partnering training components, based on Pearlin's Stress-Health Model of Family Caregiving and Rini's Social Support Effectiveness theory. The components include: 1) caregiver coaching on effective decision support (1 vs. 3 sessions); 2) caregiver decision support communication training (1 session vs. none); and 3) patient social support effectiveness psychoeducation (yes vs. no). Type: Interventional Start Date: Sep 2024 |
Prenatal Behavioral Intervention to Prevent Maternal Cytomegalovirus (CMV) in Pregnancy
University of Alabama at Birmingham
Maternal Cytomegalovirus Infections
Cytomegalovirus Congenital
This study will evaluate whether a brief prenatal clinic-based cytomegalovirus (CMV)
risk-reduction behavioral intervention will prevent maternal CMV infections during
pregnancy in women. expand
This study will evaluate whether a brief prenatal clinic-based cytomegalovirus (CMV) risk-reduction behavioral intervention will prevent maternal CMV infections during pregnancy in women. Type: Interventional Start Date: Jan 2021 |
MitraClip REPAIR MR Study
Abbott Medical Devices
Mitral Valve Regurgitation
The objective of this randomized controlled trial (RCT) is to compare the clinical
outcome of MitraClip™ device versus surgical repair in patients with severe primary MR
who are at moderate surgical risk and whose mitral valve has been determined to be
suitable for correction by MV repair surgery b1 expand
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team. Type: Interventional Start Date: Jul 2020 |
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in P1
Protara Therapeutics
Lymphatic Malformation
This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity,
and efficacy of intracystic injection of TARA-002 in participants 6 months to less than
18 years of age for the treatment of macrocystic and mixed cystic lymphatic
malformations. The Phase 2a safety lead-in, ag1 expand
This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6 months to less than 2 years. The Phase 2b is an expansion study in which enrollment of participants will be initiated after safety has been established in each cohort during the Phase 2a safety lead-in study. Each participant will receive up to 4 injections of TARA-002 spaced approximately 6 weeks apart. Type: Interventional Start Date: Oct 2023 |
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants1
Sonya Heltshe
Cystic Fibrosis
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly
effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their
impact on children with cystic fibrosis (CF). expand
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF). Type: Observational Start Date: Nov 2020 |
- Previous
- Next